These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 34522186)
1. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis. Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X Int J Med Sci; 2021; 18(15):3588-3598. PubMed ID: 34522186 [No Abstract] [Full Text] [Related]
3. LncRNA RHPN1-AS1 Promotes Cell Proliferation, Migration and Invasion Through Targeting miR-7-5p and Activating PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma. Song XZ; Ren XN; Xu XJ; Ruan XX; Wang YL; Yao TT Technol Cancer Res Treat; 2020; 19():1533033820957023. PubMed ID: 32910747 [TBL] [Abstract][Full Text] [Related]
4. PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling. Jiang H; Zhou Z; Jin S; Xu K; Zhang H; Xu J; Sun Q; Wang J; Xu J Cancer Sci; 2018 May; 109(5):1414-1427. PubMed ID: 29603830 [TBL] [Abstract][Full Text] [Related]
5. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway. Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106 [TBL] [Abstract][Full Text] [Related]
6. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway. Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734 [TBL] [Abstract][Full Text] [Related]
7. LncRNA DCST1-AS1 accelerates the proliferation, metastasis and autophagy of hepatocellular carcinoma cell by AKT/mTOR signaling pathways. Li J; Zhai DS; Huang Q; Chen HL; Zhang Z; Tan QF Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6091-6104. PubMed ID: 31364110 [TBL] [Abstract][Full Text] [Related]
8. AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway. Zhu G; Luo L; He Y; Xiao Y; Cai Z; Tong W; Deng W; Xie J; Zhong Y; Hu Z; Shan R Mol Carcinog; 2024 Sep; 63(9):1814-1826. PubMed ID: 38874176 [TBL] [Abstract][Full Text] [Related]
9. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN. Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796 [TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway. Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway. Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051 [TBL] [Abstract][Full Text] [Related]
12. Zyxin promotes hepatocellular carcinoma progression via the activation of AKT/mTOR signaling pathway. Cai T; Bai J; Tan P; Huang Z; Liu C; Wu Z; Cheng Y; Li T; Chen Y; Ruan J; Gao L; DU Y; Fu W Oncol Res; 2023; 31(5):805-817. PubMed ID: 37547758 [TBL] [Abstract][Full Text] [Related]
13. Transcription factor 7 like 2 promotes metastasis in hepatocellular carcinoma via NEDD9-mediated activation of AKT/mTOR signaling pathway. Tang L; Xu S; Wei R; Fan G; Zhou J; Wei X; Xu X Mol Med; 2024 Jul; 30(1):108. PubMed ID: 39060928 [TBL] [Abstract][Full Text] [Related]
14. Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Wang X; Han L; Zhang J; Xia Q Dig Dis Sci; 2015 Oct; 60(10):3011-8. PubMed ID: 26055238 [TBL] [Abstract][Full Text] [Related]
15. MiR-92a-3p Promotes the Malignant Progression of Hepatocellular Carcinoma by Mediating the PI3K/AKT/mTOR Signaling Pathway. Wang L; Cui M; Qu F; Cheng D; Yu J; Tang Z; Cheng L; Wei Y; Wu X; Liu X Curr Pharm Des; 2021; 27(29):3244-3250. PubMed ID: 34126886 [TBL] [Abstract][Full Text] [Related]
16. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816 [TBL] [Abstract][Full Text] [Related]
17. Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways. Li Y; Xiong H BMC Cancer; 2022 Mar; 22(1):298. PubMed ID: 35313850 [TBL] [Abstract][Full Text] [Related]
18. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway. Wang B; Song K; Chen L; Su H; Gao L; Liu J; Huang A Cell Biochem Funct; 2020 Jul; 38(5):642-650. PubMed ID: 32162707 [TBL] [Abstract][Full Text] [Related]
19. LncRNA OR3A4 participates in the angiogenesis of hepatocellular carcinoma through modulating AGGF1/akt/mTOR pathway. Li W; Fu Q; Man W; Guo H; Yang P Eur J Pharmacol; 2019 Apr; 849():106-114. PubMed ID: 30710550 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway. Zhang Y; Guo X; Xiong L; Yu L; Li Z; Guo Q; Li Z; Li B; Lin N Mol Cancer; 2014 Nov; 13():253. PubMed ID: 25424347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]